Physician profile
Sukumar Ethirajan
NPI 1396716056
$61,345.73
in general payments reported to CMS, 2019-2025
31 companies · $639 in 2025
The $639 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,450 · 2020: $14K · 2021: $24K · 2022: $9,260 · 2023: $10K · 2024: $1,006 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,075 · Food and Beverage: $2,758 · Travel and Lodging: $1,091 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,075.00 |
| Food and Beverage | $2,757.52 |
| Travel and Lodging | $1,090.63 |
| Education | $104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23,622.58 | 2019-2022 | |
| Roche Molecular Systems, INC. | $12,386.28 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $10,293.79 | 2021-2025 | Pluvicto |
| Pfizer INC. | $5,336.18 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $3,512.61 | 2019-2025 | Provenge |
| Astrazeneca Pharmaceuticals Lp | $2,008.37 | 2020-2024 | Lynparza |
| Janssen Biotech, INC. | $1,497.22 | 2019-2024 | Erleada |
| Astellas Pharma US INC | $873.83 | 2019-2025 | Xtandi |
| Abbvie INC. | $343.94 | 2019-2024 | |
| Blue Earth Diagnostics | $315.80 | 2020-2025 | Posluma |
| E.R. Squibb & Sons, L.L.C. | $208.55 | 2019 | |
| Merck Sharp & Dohme LLC | $186.52 | 2021-2025 | Lynparza |
| Amgen INC. | $167.26 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $81.35 | 2019-2023 | Darzalex, Tecvayli |
| Ferring Pharmaceuticals INC. | $71.41 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $53.10 | 2021-2022 | |
| Urogen Pharma, INC. | $51.90 | 2024 | |
| Becton, Dickinson and Company | $42.31 | 2023 | Bard Urinary Drainage Bag |
| Eisai INC. | $38.93 | 2019-2022 | |
| Exelixis INC. | $35.44 | 2019-2025 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $30.44 | 2020-2023 | Yonsa |
| Tolmar, INC. | $28.70 | 2024 | |
| Myriad Genetic Laboratories, INC. | $26.03 | 2021 | |
| Genzyme Corporation | $21.60 | 2020 | |
| Foundation Medicine, INC. | $18.70 | 2023 | |
| Axonics, INC. | $16.83 | 2020 | |
| Accord Healthcare, INC. | $16.70 | 2022 | |
| Teleflex LLC | $15.99 | 2022 | |
| Telix Pharmaceuticals | $15.00 | 2023 | Illuccix |
| Verity Pharmaceuticals INC. | $14.44 | 2025 | Trelstar |
| Acrotech Biopharma INC. | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukumar Ethirajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.